• Dual actions of a single compound with both antibiotic and immunomodulatory effects can suppress inflammation and promote tissue regeneration. • Fast-dissolving microneedle patch enables minimally ...
Solu Therapeutics has debuted with $31 million in seed financing to develop a small-molecule drug technology licensed from GSK. Called Cytotoxicity Targeting Chimera, or CyTaC, the technology results ...
Researchers from China Pharmaceutical University have reported the discovery and preclinical evaluation of novel bifunctional molecules inducing DNA damage and targeting PARP for the treatment of ...
WALTHAM, Mass.--(BUSINESS WIRE)--Avilar Therapeutics, a biopharmaceutical company focused on extracellular protein degradation, today announced it will present preclinical proof-of-concept data for ...
WALTHAM, Mass.--(BUSINESS WIRE)--Avilar Therapeutics, a biopharmaceutical company focused on extracellular protein degradation, today announced it will present new preclinical data from its ATAC ...
Scientists in Japan have fabricated an inverted pervoskite cell with a new bond/charge regulated defect passivation technique consisting of introducing bifunctional molecules onto the perovskite ...
Researchers at Peking Union Medical College Hospital have mapped out why pairing two well-known cancer drugs can turn “sleepy” immune cells back into tumor killers. In a new Perspective published ...
On April 8, 2022, ESSA Pharma, Inc. EPIX announced that preclinical data for the company's first-generation androgen receptor (AR) ANITen bAsed Chimera (ANITAC™) N-terminal domain (NTD) degraders was ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results